Zolpidem Reference

Plain English

What it is

Zolpidem, sold as Ambien, is a prescription sleep medicine first approved by the FDA in 1992 for short-term insomnia (trouble sleeping). It is a sleeping pill in the group nicknamed Z-drugs that calms brain activity to help you fall asleep, and it is a controlled substance (Schedule IV) because it can be habit-forming.

What people use it for

People take it for short-term trouble falling asleep and staying asleep. It is one of the most commonly prescribed sleep medicines.

What the science shows

Research supports it for short-term insomnia. In one study where people took it only on some nights instead of every night, their sleep stayed better over about three months, and the trouble sleeping did not bounce back between the nights they took it.

The catch

It carries the FDA's strongest alert, a Boxed Warning: some people have done things while not fully awake, such as sleep-walking, sleep-driving, and other activities they do not remember, and a few of these have caused serious injury or death. It can also become habit-forming as the body comes to depend on it, and it can leave you drowsy and less alert the next morning, which can affect driving.

Reference summary

Perlis 2004 J Clin Psychiatry studied long-term non-nightly zolpidem dosing in adults with primary insomnia. The label-level efficacy is well-established for short-term sleep-onset and sleep-maintenance use. The FDA reduced recommended doses for women in 2013 due to next-morning impairment data (5 mg immediate-release, 6.25 mg extended-release for women; men can use the original 10 mg / 12.5 mg).

Regulatory and posture

Categories

Sleep

Aliases

Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist, Non-benzodiazepine GABA-A agonist (small molecule, not a peptide)

Evidence posture

human - Complex sleep behaviors (sleep-walking, sleep-driving, sleep-eating with no memory) carry a label-level Boxed Warning since 2019. Next-morning impairment is dose-dependent and well documented.

Regulatory status

FDA-approved as Ambien (1992) for short-term treatment of insomnia, with subsequent approvals for extended-release (Ambien CR, 2005), sublingual (Edluar, 2009), low-dose middle-of-the-night sublingual (Intermezzo, 2011), and oral spray (Zolpimist) formulations. Schedule IV controlled substance.

Content review status

label verified